Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-CONIC
2024-511141-19-00Phase 2Authorised
- Sponsor
- Region Västra Götaland
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in triple-negative breast cancer (TNBC), sponsored by Region Västra Götaland. Primary endpoints: Conversion of ER expression from 0% to ≥2%, Conversion of ER expression from 1–9% to ≥10% and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2024-511141-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511141-19-00.